Literature DB >> 21264529

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.

Jiehua He1, Roujun Peng, Zhongyu Yuan, Shusen Wang, Jiewen Peng, Guinan Lin, Xiaomei Jiang, Tao Qin.   

Abstract

The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from January 1995 to December 2008. AR expression was found in 25.8% of the cases with TNBC. TNBC patients with AR negative have a higher proportion of positive lymph node. A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS). Univariated analysis indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate analysis indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients. Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC. Therefore, TNBC may be further divided into two subtypes according to AR status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264529     DOI: 10.1007/s12032-011-9832-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  15 in total

Review 1.  Androgens and androgen receptor: do they play a role in breast cancer?

Authors:  M Bryś
Journal:  Med Sci Monit       Date:  2000 Mar-Apr

Review 2.  Roles of androgens in the development, growth, and carcinogenesis of the mammary gland.

Authors:  Dezhong J Liao; Robert B Dickson
Journal:  J Steroid Biochem Mol Biol       Date:  2002-02       Impact factor: 4.292

3.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

4.  Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

Authors:  Ana M Gonzalez-Angulo; Katherine Stemke-Hale; Shana L Palla; Mark Carey; Roshan Agarwal; Funda Meric-Berstam; Tiffany A Traina; Clifford Hudis; Gabriel N Hortobagyi; William L Gerald; Gordon B Mills; Bryan T Hennessy
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

Authors:  S L Hines; L A Vallow; W W Tan; R B McNeil; E A Perez; A Jain
Journal:  Ann Oncol       Date:  2008-06-05       Impact factor: 32.976

7.  Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations.

Authors:  S Nicholas Agoff; Paul E Swanson; Hannah Linden; Stephen E Hawes; Thomas J Lawton
Journal:  Am J Clin Pathol       Date:  2003-11       Impact factor: 2.493

8.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.

Authors:  Nancy U Lin; Elizabeth Claus; Jessica Sohl; Abdul R Razzak; Amal Arnaout; Eric P Winer
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

9.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Authors:  Marc Tischkowitz; Jean-Sébastien Brunet; Louis R Bégin; David G Huntsman; Maggie C U Cheang; Lars A Akslen; Torsten O Nielsen; William D Foulkes
Journal:  BMC Cancer       Date:  2007-07-24       Impact factor: 4.430

10.  Breast cancer subtypes and survival in patients with brain metastases.

Authors:  Byung-Ho Nam; Sun Young Kim; Hye-Sook Han; Youngmee Kwon; Keun Seok Lee; Tae Hyun Kim; Jungsil Ro
Journal:  Breast Cancer Res       Date:  2008-02-28       Impact factor: 6.466

View more
  65 in total

1.  Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.

Authors:  Arvydas Laurinavicius; Aida Laurinaviciene; Valerijus Ostapenko; Darius Dasevicius; Sonata Jarmalaite; Juozas Lazutka
Journal:  Diagn Pathol       Date:  2012-03-16       Impact factor: 2.644

Review 2.  Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Authors:  Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina
Journal:  Endocr Relat Cancer       Date:  2015-02-26       Impact factor: 5.678

3.  Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.

Authors:  J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

4.  Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.

Authors:  Elgene Lim; Min Ni; Shiliang Cao; Aditi Hazra; Rulla M Tamimi; Myles Brown
Journal:  Curr Breast Cancer Rep       Date:  2014-06-01

Review 5.  Impact of estrogens in males and androgens in females.

Authors:  Stephen R Hammes; Ellis R Levin
Journal:  J Clin Invest       Date:  2019-05-01       Impact factor: 14.808

6.  Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Authors:  Ke-Da Yu; Rui Zhu; Ming Zhan; Angel A Rodriguez; Wei Yang; Stephen Wong; Andreas Makris; Brian D Lehmann; Xi Chen; Ingrid Mayer; Jennifer A Pietenpol; Zhi-Ming Shao; W Fraser Symmans; Jenny C Chang
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

Review 7.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 8.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

9.  Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer.

Authors:  Jie-Hua He; Rong-Zhen Luo; Mu-Yan Cai; Mei Li; Jia-Bing Lu; Zhong-Yu Yuan
Journal:  Med Oncol       Date:  2013-01-24       Impact factor: 3.064

10.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.